Fate Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 56.36 million compared to USD 68.62 million a year ago. Basic loss per share from continuing operations was USD 0.58 compared to USD 0.72 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.555 USD | -4.71% | -15.33% | +21.79% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.79% | 517M | |
-0.49% | 105B | |
+3.31% | 97.5B | |
+2.39% | 22.19B | |
-16.16% | 21.33B | |
-6.82% | 18.68B | |
-41.41% | 16.6B | |
-22.87% | 14.52B | |
+6.32% | 14.09B | |
+21.46% | 10.99B |
- Stock Market
- Equities
- FATE Stock
- News Fate Therapeutics, Inc.
- Fate Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022